Late Breaking Abstract

It certainly is an exciting time here at ANZUP as we barrel into our second decade of existence.

Last month we announced that ANZUP’s ENZAMET trial will feature in the ASCO 2019 main plenary session, with Professor Christopher Sweeney presenting the results. This is an amazing achievement; more than 6,200 abstracts are submitted to ASCO, and only the top four, the ones most likely to be of international interest and to influence global practice, are chosen for the Plenary Session.

We look forward to sharing more details about the study results following ASCO in June. We acknowledge and thank the patients for their participation in the study; and the principal investigators, co-investigators, and study coordinators at the 83 centres across Australia, New Zealand, Canada, United Kingdom and Ireland for their dedication and enthusiasm.

We also acknowledge the University of Sydney (Sponsor) and the NHMRC CTC staff in coordinating this international trial.

ANZUP’s membership has grown to over 1,500 members across more than 20 disciplines. We currently have multiple trials recruiting across all the cancers we represent, as well as several in follow-up and some exciting trials in development. You will read about some of those in this newsletter, and we will continue to communicate over the coming weeks and months.

We could not do what we do without all of you, so I thank you for making this happen.

MARGARET MCJANNETT
ANZUP CEO

Join us at ANZUP’s Annual Scientific Meeting at the Hilton in Brisbane on 21-23 July

I am delighted to be working with the 2019 Convening Committee to bring you a program showcasing world-class, cutting edge presentations from an outstanding national and international faculty. The ASM theme “Making Connections” revolves around how we can improve patient and care givers access to the right information, supportive care and clinical trials while encouraging links between the various health disciplines, researchers and cross border collaborations. We will also explore strategies for connecting under-represented populations to clinical trials (eg rare cancers, geriatrics, rural and remote populations).

We have confirmed a superb international faculty including Kelly Parsons, Phuoc Tran, Alison Birtle, Catherine Paterson and Elizabeth Plimack. Delegates will have the opportunity to interact with and learn from our five international experts and numerous national leaders in the management of GU cancers.

The MDT Masterclass will once again challenge our local and international multidisciplinary panel and educate all with real-life clinical challenges. The Translational Symposium will feature Phuoc Tran and Elizabeth Plimack and some great Australian speakers. The ANZUP PCFA Nurses Symposium will provide opportunity for GU Nurses from around the country to meet and network. A Community Engagement Forum “a little below the belt” will be open to the public on Sunday 21 July. The preliminary program is now available on the ANZUP website – www.anzup.org.au.

Applications for the ANZUP/AstraZeneca Travel Fellowships and Trial/Study Coordinator Scholarships are available until Monday May 13, and early bird registrations also close on 13 May.

We look forward to welcoming you to Brisbane for an exceptional educational event. For more information visit - https://www.anzup.org.au/content.aspx?page=asm-news.

DAVID PRYOR
Convenor
Welcome to this edition of UPdate, the newsletter of the Australian & New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP)!

“Life is just one damn thing after another.” – Anonymous

“Life is what happens to you while you’re busy making other plans.” – John Lennon

“Yay, more emails!” – Nobody, ever

All these sayings are very true, especially at this time of year. The new year is now a bit shabby and tattered around the edges, being 25% over; the holidays (assuming there were any!) are a distant memory; some of us have just emerged blinking from a whirlpool of grant-writing, while others are about to descend into one; tiny things mount up to overwhelming mountains; and the day to day business and busyness of life just goes on and on. It’s exhausting and often very tedious.

What? No. Ian: stop, before people think you are feeling sorry for yourself. Everyone reading this has their own challenges. So many of the people we care for do not get these opportunities of intense work, productivity, and yes, tedium. Their lives are bracketed on one side by the day they were told about their cancer, and on the other side by the day that cancer will steal the other days they should have had. The people who love them not only have to experience the same anguish, but somehow will have to go on with their lives afterwards. It’s not fair, it’s not right, and it makes me look at my own complaints in a very different light. How can I begrudge it, when after all I’m doing it to try to improve outcomes for people who just do not have the same luxury of time as me?

Let’s reframe the problem, then. I did have some time off with my family, whom I love and who support me even as I’m writing these words after hours (I’ll be home soon, my love). I’m privileged to be able to work for people affected
by cancer and perhaps to make a difference. I have the amazing opportunity to undertake research and to work with teams of people who really make a difference. There is profound beauty in so many of the tiny things, if we can take a moment to notice them. The day to day busyness of my life just goes on and on. Not everyone can say that! I am incredibly blessed.

On top of all that, all of us reading this newsletter get to work with ANZUP and so to be part of a whole that is much greater than its components. ANZUP has a growing international reputation as an organisation that works effectively in consultation with its partners and the community to generate new evidence to improve outcomes for people affected by genitourinary cancers. I recently had the privilege of being part of the 2019 ASCO Genitourinary Cancers Symposium and I was struck by how often ANZUP’s members and their work appeared. Trials that we started several years ago remain relevant today and the world is watching expectantly to see the outcomes (hint: look out for the ASCO 2019 Plenary Session). New ideas keep flowing through our creative engine rooms and will lead to future trials that are also based on a clear understanding of clinical needs and the new opportunities represented by the science.

The ANZUP Scientific Advisory Committee met in February for a “horizon scanning” meeting. This all-day meeting allowed us to review our research priorities and to address specific questions, such as key issues for each disease type or discipline; requirements for technology or other platforms; how to better involve more clinical sites, regions, and patient groups; processes for concept development and prioritisation; communication strategies; and novel models of research. You will see the outcomes of this becoming reflected in the subcommittee agendas, and in the Concept Development Workshops taking place during April and May. We expect many of these ideas to evolve into new trials or supporting research.

Of course we are now very well advanced in planning for the Annual Scientific Meeting to be held in Brisbane on 21-23 July 2019, under the leadership of convenor David Pryor and his fantastic convening committee. You will read more details of the ASM elsewhere in these pages, but you can be assured that we will continue to try to grow the areas that have worked so well in recent years, as well as introducing a few new ideas. Make sure you block out the time now to allow yourself to attend, and register!

There will be many other opportunities for you to be involved as well. We will continue to offer fellowships and grants, and to provide educational opportunities such as our successful preceptorship programs and the Best of GU symposia. You might also want to take an additional step and help us directly with our fundraising. The Melbourne Below the Belt Pedalthon took place on Sunday 17 March 2019 at Sandown, with the great support of the Melbourne Racing Club Foundation. Once again this was a fun family day that was uplifted further by the knowledge that everyone involved was working in a very practical way to build more resources for future research. If you missed it (or even if you didn’t), don’t worry: the Sydney Pedalthon is on again at Eastern Creek on 10 September 2019, and as always you are most welcome to come and ride, participate in the fundraising, or both. The ANZUP Board has continued its commitment that all funds raised through the Pedalthons are reinvested back to support research projects intended to lead to future clinical trials. It has been a great highlight of the Pedalthons in recent years to hear from past recipients of the Below the Belt Research Fund grants and how they have used these resources to progress their research. Phew. It’s a lot to take in. I’m exhausted just writing about it. It’s frantically busy and sometimes a bit overwhelming. It just keeps on going, getting bigger and increasing momentum. Isn’t it wonderful to be part of it?

Please enjoy this edition of UPdate.

IAN DAVIS
ANZUP Chair
If I have a thousand ideas and only one turns out to be good, I am satisfied.

– Alfred Bernhard Nobel

The starting point for every new clinical trial or study is an idea or concept. The ideas behind ANZUP’s clinical trials are often first presented at one of four disease-specific face-to-face Concept Development Workshops. Held annually in the second quarter of the year, ANZUP’s CDWs provide an invaluable opportunity to discuss GU oncology ideas or concepts with a multidisciplinary team.

Formally established in 2014, the CDW series is designed to facilitate and support active ANZUP members who have an idea/concept they would like to put forward for discussion and, if supported, to further develop into a future grant application.

Emerging research, trainee and recent graduate members are also strongly encouraged to attend the workshop(s) as an educational opportunity, even if they are not presenting a concept themselves.

Last year’s CDWs were attended by 100 multidisciplinary members and provided thought-provoking discussion on both the scientific merit and practicalities of the proposals put forward.

In early March, 15 people attended the first Quality of Life & Supportive Care CDW held in Sydney and chaired by Haryana Dhillon, and 3 concepts were presented.

Our newly renamed BUP (Bladder, Urothelial and Penile Cancer) CDW was also held in Sydney in April with 23 attendees and 5 concepts presented.

In late April our Germ Cell CDW was held at Peter MacCallum in Melbourne. It was great to see over 20 attendees and 5 concepts presented. In early May Dr Craig Gedye led the Renal Cell CDW in Sydney. Close to 20 people attended and there were 2 concepts presented with some robust group discussions about gaps in research and opportunities.

**CDW calendar**

**Prostate**

**Workshop date:** Friday, 17 May 2019

**Venue:** Pullman Sydney Airport, 191 O’Riordan Street, Mascot, NSW

Funding is available to support attendance for successful applicants should this be required.

If you have an idea/concept you would like to submit please complete the attached ANZUP Concept Outline Submission Form and return to anzup@anzup.org.au by the deadlines detailed above. This form is also available through the Member Resources page of the ANZUP website.
The ANZUP Scientific Advisory Committee (SAC) met in Melbourne on Friday 1 February 2019 for a “horizon-scanning” strategic planning meeting. This meeting arose out of previous strategic planning meetings but was intended to address very practical issues. The agenda allowed a wide-ranging discussion and included:

• Review of the ANZUP research strategy and priorities
• Disease-based priorities. What are the current issues for each disease type? Which of these might be able to be addressed through ANZUP? How do we keep track of new science and new opportunities? What platforms do we need for research support?
• Discipline-based priorities. Where are the current gaps for our various discipline? What is new in these fields? What does the community tell us about what is important?
• Specific issues. How do we better involve rural or regional sites? What is the role of teletrials? How do we get more trials into New Zealand? Are there questions relevant to specific groups we should consider, such as ATSI or CALD populations? How should we link productively with other groups?
• Concept development. How can we improve the concept development process?
• Communication. How do we let our members know the outcomes of our strategic planning and encourage them to generate ideas accordingly? How do we formalise two-way communication with other stakeholder groups and the wider community?
• What novel models of research should we consider?

The day was highly productive and has changed the way the SAC will think about these issues. SAC meetings will concentrate more on questions such as these and less on matters of routine reporting, although the SAC will continue to have overall scientific oversight of ANZUP’s programs.

Thank you to all the SAC members, including deputy chairs and ANZUP staff, who contributed so productively on the day. Thanks also to all of you who continue to contribute to ANZUP’s mission in so many ways. You might wish to be more actively involved – please let us know if you want to be added to any committee mailing list, or if there are other ways that you want to contribute.

IAN DAVIS
Chair, ANZUP Scientific Advisory Committee
Recent News

1. New name for the bladder subcommittee... BUP! – Bladder, Urothelial and Penile Cancer Subcommittee

Following discussions amongst the subcommittee and the SAC, we decided to change the name of the subcommittee to recognise the entire range of malignancies dealt with by the group. Whilst there was some debate about the acronym (you can guess what!), ultimately we agreed on BUP.

2. BCGMM trial gets NHMRC funding to complete the study.

Congratulations to all those ANZUP members who worked so hard both on previous and this recent successful application which has secured the funding to complete this important trial. With increased site payments and the costs of the mitomycin fully funded new sites previously unable to participate can now join Australia's biggest bladder cancer trial.

3. BCG supply shortage ...again!

Whilst it is disappointing that we face further BCG shortages, this supply issue will be less serious than the issues we faced in 2016 and it is estimated that ANZ supply may fall by 20%. Remember that patients enrolled into the BCGMM trial use significantly less BCG than those treated on a standard Lamm schedule.

4. PCR MIB

This important phase 2 study continues to recruit steadily with 15 patients recruited currently. If you have a suitable patient, please refer to your nearest site that is open to the study. You can read more about the trial on the ANZUP website.

5. Feasibility of water irrigation post TURBT for NMIBC

It’s great to see the Below the Belt Research Fund in action and one of last year’s recipients - Shomik Sengupta and his study moving to the next stage. We are applying for a grant to request funding for a randomised phase 3 trial comparing water irrigation with immediate post-resection chemotherapy to reduce the risk of recurrence for non-muscle invasive bladder cancer NMIBC. If the funding is secured, we are hoping to open the study in 2020.

Calling All Radiation Oncologists

The BUP Subcommittee would love to develop more trials in the BUP space involving radiation oncology. If you are a radiation oncology trainee or consultant and you want to get involved please contact me at dickon.hayne@uwa.edu.au

DICKON HAYNE
Chair, Bladder Subcommittee

Update your member details now!

Need to update your contact details or subscription preferences?

Update your member details now at www.anzup.org.au/member/updateprofile.aspx to stay up to date on all the latest ANZUP news and events.
It’s been another busy quarter in the renal cancer subcommittee and, with ongoing brisk activity, new open trials, and further development in new protocols that forthcoming.

The UNISoN study continues to recruit strongly, showing the extraordinary strength of network of sites across the country, and the unmet need of this group of patients with rare cancers. We are once again very grateful to the teams around Australia working on this study together. Almost every site has recruited at least one patient, with the Sunshine Coast Hospital led by Dr Michelle Morris as the latest site to recruit a patient.

The KEYPAD study continues to recruit solidly, again with sites across Australia recruiting well. There is increasing interest in the use of additional agents to modulate the immune response and augment checkpoint immunotherapy, with a number of clinical trials internationally combining denosumab with checkpoint inhibitors. With the comprehensive collection of bio specimens as part of the KEYPAD study, we will be in an extraordinary position to answer questions about RANKL and how this influences the anti-cancer immune response.

In the last quarter congratulations should also go to Dr David Pook and Dr Carol Harris who have been working with ANZUP and BaCT to develop the UNICAB study which will open soon at sites across Australia to test the efficacy of cabozantinib in people who have taken immune checkpoint inhibitors for non-clear cell kidney cancer.

The Renal Cell Concept Development Workshop held in early May was a great opportunity to both hear new concepts, as well as some healthy group discussions about the gaps in research and opportunities.

CRAIG GEDYE
Chair, RCC Committee

Recent News

1. A Concept Development Workshop (CDW) of our own

We kicked off this year’s ANZUP CDW’s with one dedicated to Quality of Life (QoL) and Supportive Care ideas. Judging by the level of interest there is going to be plenty of work for us to do over the next few years.

As you will recall from previous newsletters our members have been very effective in obtaining funding for pilot projects through the Below the Belt Pedalthon Research Fund. As a result, there will be several projects completing over the next 12 months, providing ample opportunity to incorporate some of these interventions and initiatives into ANZUP trials into the future. This will allow assessment of impact on symptoms, psychosocial, and behavioural outcomes as well as disease related outcomes where relevant. Please do stay tuned and start thinking about how these interventions can be incorporated into your own trials and, indeed, into routine practice.

2. Representation at disease specific CDWs

While members of the QoL and Supportive Care Subcommittee have been present at many CDWs, we have now identified at least two people who will regularly attend the CDWs and meetings of each disease site specific group. Our aim in doing this is to increase links between our subcommittee and each of the ANZUP focus areas to facilitate increased involvement of supportive care and QoL in ongoing projects. We also hope it will help us to identify the issues relevant to ANZUP patients and their families that are common across the tumour groups. Thus we should be able to mount some major psychosocial and supportive care initiatives within the ANZUP trials portfolio to improve care and access for patients.

3. Deputy Chair

I would like to announce Catherine Paterson as the Quality of Life and Supportive Care Subcommittee Deputy Chair. Catherine will work alongside myself to facilitate the inclusion of a supportive care perspective in ANZUP led concepts and protocols. Welcome Catherine!

Coming Up

QoL & Supportive Care Committee meetings. With so much activity within our area we have committed to holding regular committee meetings. The first will follow soon after the last of the tumour site CDWs to allow us to regroup and consider where our focus needs to be over the next 6 to 12 months to contribute best to the work of ANZUP.

HARYANA DHILLON
Chair, QoL and Supportive Care Subcommittee
There continues to be no shortage of activity in all aspects of the prostate cancer subcommittee. It is hard to believe, but it is just on 5 years since we activated our duo of enzalutamide studies, ENZAMET and ENZARAD. With both fully accrued and in follow-up, we eagerly await the first analyses, with ENZAMET especially close to its first interim analysis. Fingers crossed for big news there. We continue to assimilate a substantial biorepository around these studies will provide an enduring resource for future interrogation. The international translational research committee welcome your ideas for study of these samples.

Our other actively recruiting ANZUP-led studies are also progressing. The Pain-Free TRUS B randomised trial is quickly closing in on the accrual target of 420 thanks to ongoing contributions from our NZ study leaders. Similarly, the randomised trial of cabazitaxel chemotherapy against Lutetium-PSMA in castrate-resistant disease (TheraP) is two-thirds accrued now with great ongoing interest. The role of ANZUP as leaders of the health economics arm of the global Intermediate Clinical Endpoint initiative (ICECaP) has also had a boost with a PhD student recently commencing within the project.

Of our co-badged studies, proPSMA (with ARTnet and TROG) has rapidly completed accrual of 300 men randomised between conventional and PSMA-PET imaging. With a six month accuracy endpoint, this has the potential to produce practice-changing results within a year. The RAVES study (with TROG and USANZ) looking at adjuvant against early salvage radiotherapy after prostatectomy is in the final analysis phase and we should hear results at a major meeting very soon. Now more than a decade after inception, these results are eagerly awaited internationally. We have also added the NINJA study (TROG-led) to our portfolio – assessing two novel hypofractionated approaches to radiation therapy for early prostate cancer.

Several exciting concepts are continuing in development. A large global follow-up study to ENZARAD has largely completed protocol writing, with the delicate commercial and collaborative group agreements coming together well. We anticipate a rush of activity on this in the near future. Other exciting concepts around biomarker implementation and earlier use of Lutetium-PSMA use are also well developed now, while a number of concepts and Below-the-Belt funded studies are progressing well.

I would like to take the opportunity to encourage all to participate in the prostate cancer concept development workshop in Sydney on May 17. No matter how small or simple you may think an idea to be, we would like to hear them! Good clinical questions make good study ideas, so even if you don’t feel you have the skills to take an idea forward to a full study, we have a very collegiate and experienced team of collaborators can help make it happen, so please think about participating.

SCOTT WILLIAMS
Chair, Prostate Cancer Subcommittee

ARUN AZAD
Chair, Translational Research Subcommittee
Recent news

1. TIGER study is now open at multiple sites in Australia and recruiting patients. This is one of the most important studies in germ cell cancer for some time, comparing TIP versus TICE (high dose with stem cell rescue) as first salvage for platinum refractory disease.

2. iTestis continues to recruit patients, looking for additional sites. This is a testicular cancer registry, supported by ANZUP, that hopes to engage as many sites and clinicians as possible. Please contact Ben Tran if you are interested in participating. Data collection support can be provided.

3. P3BEP continues to recruit well, and has been successful in gaining additional funding through Cancer Australia. Well done to the Peter Grimison and team on such a successful grant application!

4. The ANZUP surveillance guidelines for patients with advanced disease who have completed curative chemotherapy is now available on the ANZUP website.

Coming up

Micro RNA analyses appear to be a promising biomarker for testicular cancer, both seminoma and non-seminoma. A children’s oncology group study is currently enrolling patients internationally, and also through paediatric centres in Australia. A SWOG study is aiming to begin in late 2019. ANZUP is working hard to gain funding to participate in one of these studies, and contribute to what we expect to be a major step forward for testicular germ cell cancers.

Concept Development Workshop

We had an excellent turn out at the Germ Cell Tumour CDW held at Peter Mac on 30 April 2019. At one stage the urologists outnumbered the medical oncologists, which was nice to see! Several exciting proposals were discussed, with the most likely to move forward including a surgical study for stage 2A/B seminoma, collection of blood specimens in stage 1 testicular cancer for miR-371 studies and a potential national survivorship care plan. Hopefully, next year, we’ll be talking about recruiting patients to these studies!

BEN TRAN
Chair, Germ Cell Subcommittee
The CAP held its first teleconference on Thursday 14 March. It was good to catch up again and start to focus on the year ahead, and discuss how we can best support ANZUP.

**Membership News**

2019 marks a number of CAP members reaching their second 3 year term. An expression of interest to take on a further 3 year term was sought from members.

Sadly we said farewell to Peter Stanford (bladder cancer) and Jason Gray (testicular cancer) from the CAP! We thank both Peter and Jason for their valued contribution over the years, and for sharing their personal cancer diagnosis experiences.

Peter at the age of 82 is retiring from the CAP but will remain a Friend of ANZUP. Peter has well and truly earnt a bit more retirement time!

Jason is at the other end of his career, currently working through his training to become a GP and with a very young family you can only stretch so far. Jason will remain an ANZUP member as he is keen to keep in contact. We wish both Peter and Jason all the best for the future; it has been great having you both on board.

The call for new CAP members has been put out through the ANZUP sub committees. Marg and I are keen for members to consider referring any patients who may be interested in contributing to our ANZUP CAP. Thanks to those of you who have done so already, and we will be following this up over the coming months. We look forward to welcoming new members to the CAP during 2019!

**Research Activities and Meetings**

During January, CAP members were asked to provide feedback for one of the BTB Grant Recipients Ben Smith for his project ‘Developing & Piloting of a Question Prompt List (QPL)’ to aid informed treatment and decision making in men diagnosed with Localised Prostate Cancer. Thanks to Ray and Colin who assisted Ben.

The recent Horizon Scanning meeting was attended by Ray Allen as Deputy Chair of the CAP. Ray said the meeting was very informative, and a great platform for having a focussed discussion highlighting a range of important issues.

The inaugural QoL Concept Development Workshop held in March was attended by Leonie Young. Leonie found it to be an excellent day with good discussion across the multidisciplinary group with a number of ideas being put forward.

There have been some preliminary discussions around the CAP education session and the Community Engagement Forum being held at the at the 2019 ASM on the afternoon of Sunday 21 July. Please consider promoting this free informative afternoon to your patients and families, in particular to those of you working in sunny Brisbane!

A couple of CAP members participated in the recent ‘Below the Belt Pedalthon’ in Melbourne - another successful ANZUP event! The effort that goes into these events to raise awareness of ANZUP and below the belt cancers is fantastic. I encourage EVERYONE to get behind these events – the next one being held in Sydney on Tuesday 10 September. It’s always a great day to be part of!

We are looking forward to another productive year as we continue to assist ANZUP members in your research projects.

**BELINDA JAGO**

Chair, CAP
**CLINICAL TRIAL UPDATES**

**BCG MM (ANZUP 1301)**
- **Study sites:** 13 sites open to recruitment
- **Recruitment:** 209 patients randomised

**KEYPAD (ANZUP 1601)**
- **Study sites:** 13 sites open to recruitment in Australia with 1 more expected in 2019
- **Recruitment:** 27 patients randomised

**Pain-free TRUS B (ANZUP 1501)**
- **Study sites:** 7 sites open and recruiting
- **Recruitment:** 363 patients randomised

**P3BEP (ANZUP 1302)**
- **Study sites:** 26 sites open and recruiting (ANZ) + 21 sites internationally
- **Recruitment:** 80 patients randomised

**PCR MIB (ANZUP 1502)**
- **Study sites:** 5 sites open to recruitment in Australia. Liverpool Hospital to open shortly
- **Recruitment:** 15 patients randomised

**TheraP (ANZUP 1603)**
- **Study sites:** 11 sites open to recruitment in Australia
- **Recruitment:** 152 patients randomised

**TIGER (ANZUP 1604)**
- **Study sites:** 4 sites open - Peter MacCallum Cancer Centre recently activated on 31 October 2018
- **Recruitment:** 3 patients randomised

**UNISoN (ANZUP 1602)**
- **Study Sites:** 19 sites open, 4th patient from Calvary Mater Newcastle has been enrolled into the UNISoN study.
  - **Recruitment:** 71 patients randomised in Part 1 & 26 patients randomised in Part 2

**UNICAB (ANZUP 1802)**
- **Study sites:** 10 sites anticipated to participate
- **Recruitment:** 48 patients planned

---

**Coming soon!**

Congratulations to A/Prof Louise Emmett, Director Theraonetics and Nuclear Medicine, St Vincent’s Hospital Sydney, who has received PCRA funding for her ANZUP led ENZA-p trial. The primary aim of the study is to evaluate the safety and efficacy of enzalutamide versus enzalutamide + Lu PSMA therapy in men with mCRPC and clinical features that predict for early treatment failure with enzalutamide alone. We anticipate the trial to open later this year across 7 sites recruiting 160 patients.

Congratulations also to Michael Hofman and Arun Azad’s “Up-Front PSMA” Alliance: Using Theraonetics Early to Eradicate Prostate Cancer and Developing Novel Strategies for PSMA-negative disease study which also received PCRA funding.

**ANZUP Co-badged Studies**

**FASTRACK II (TROG 15.03)**
- **Recruitment:** 45 patients randomised
- **Study sites:** 8 sites open and recruiting

**NMIBC-SI Evaluation**
- **Recruitment:**
  - Patients enrolled field test 1: 220 (closed - completed)
  - Patients enrolled field test 2: 63
- **Study sites:** 14 sites open

**NINJA**
- **Recruitment:** 2 patients so far
- **Study sites:** 10 sites are anticipated to participate across Australia. Currently two sites are open, Calvary Mater Newcastle and Liverpool/Campbelltown Hospital.
Our second Melbourne Pedalthon a huge success!

The second Melbourne Pedalthon on Sunday 17 March was a huge success with 34 teams and 150 riders participating and helping raise more than $77,000 for ANZUP’s Below the Belt Research Fund!

Melbourne certainly turned on the great weather for us, with sunny and warm conditions all day, which kept the riders smiling and pedalling, showing their dedication to the cause – to fight cancer below the belt.

Thank you to every rider and volunteer who joined us out at Sandown Racecourse. Our thanks also go to the Melbourne Racing Club Foundation for their generous support of the venue and to our many sponsors including Platinum Sponsor, Bristol-Myers Squibb, Silver Sponsor Ipsen and Drinks Station Sponsor, BOQ Specialist.

The family challenge was again a huge hit – with over 18 adults and kids participating, including our youngest riders ever – 2 and a half year old Henry and his cousins 4 year old Milly and Harry.

A big thank you to the many members, their families and friends, who got behind the Pedalthon by signing up teams, making donations, promoting the event and pulling on the Lycra themselves.

A special thanks to Associate Professor Andrew Weickhardt and Professor Shomik Sengupta who shared with the audience how the Below The Belt Research Fund supported their studies. Thanks also to Associate Professor Jeremy Shapiro and Dr David Pook who have been huge supporters of bringing the Pedalthon to Melbourne.

*Fundraising total stands at $77,834 at the time of publication. If you would like to support the Pedalthon and the Below the Belt Research Fund, there is still time, click here to donate.

RESULTS & PHOTOS

Full results and the Pedalthon photo album can be found on the Below the Belt Facebook page - https://www.facebook.com/BTBPedalthon/. Please like and tag yourself in the album and send any photos from the day to pedalthon@anzup.org.au so they can be added. You can also watch a video from the day here: https://t.co/gMSO1UHzEg.
“The Pedalthon was set up several years ago by Simon Clarke who was affected by genitourinary cancers and wanted to find some way of giving back to the profession.

Since then we’ve generated close to $1.5m of research funds and every dollar of that fundraising has been ploughed back in to support further research.”

Ian Davis, ANZUP Chair

“If you can get large groups of people together, have some fun while you’re fundraising doesn’t mean that every individual has to contribute large amounts of money, it’s about many hands make light work and that’s what it’s all about – trying to make a difference.”

Belinda Jago, ANZUP Consumer Advisory Panel Chair

“It’s a great day, it’s a fun day – cycling, everyone can get into it but we raise really important funds for ANZUP.”

Jeremy Shapiro, ANZUP Member

“The reason a day like today is important is that ANZUP helps to raise the funds that does that first step. So it is a key effort in terms of running ultimately those big scale studies that are going to change the practice and improve the treatments for patients with these below the belt cancers.”

Shomik Sengupta, ANZUP Board Member

“...As someone who’s heavily involved with ANZUP I can hand on heart say that this is a brilliant cause. If you want to get involved you’re more than welcome to come along, have a look at the ANZUP website and we hope to see you here next year!”

David Pook, ANZUP Renal Cell Subcommittee Deputy Chair
Call for applications

Thanks to the funds raised by the Below the Belt Pedalthon (see page 12), the Below the Belt Research Fund is able to provide support to ANZUP members in the development of investigator-initiated studies. Grants of up to $50,000 are available for successful applicants.

In 2018, much needed seed funding was provided to assist eight ANZUP members in progressing new trial ideas to the point of becoming full scale studies. Find out more about the work our members are doing on our website under Grants & Awards > BTB Research Fund (http://www.anzup.org.au/content.aspx?page=btbresearchfund).

The 2019 Below the Belt Research Fund grant applications are now open. Eligible research projects may include pilot studies, translational research that may lead to an ANZUP project or form part of an existing project, innovative sub-studies, and seed funding to start a high priority ANZUP study that has a high likelihood of receiving ongoing funding from another source.


Submissions close Monday 27 May 2019.

ANZUP Astellas Young Investigator of the Year Award

The Astellas Young Investigator of the Year Award recognises an outstanding early year career researcher in prostate cancer clinical trials research with up to $10,000 to support his/her attendance at an international GU meeting and the ANZUP ASM. Applications close Friday 1 June.

ANZUP Trial/Study Coordinator Scholarships

ANZUP encourages and supports Trial/Study Coordinators working on ANZUP trials to attend the 2019 ASM by providing a full conference registration. To be considered eligible for a scholarship you must be an ANZUP member. Visit www.anzup.com.au to join. Applications close Monday 13 May.

ANZUP/AstraZeneca Travel Fellowships

Travel fellowships are open to members who have had an abstract or concept accepted for either oral or poster presentation at the 2019 ASM. Fellowships will be awarded up to the value of $800 for travel and expenses incurred to attend the ASM in July. Applications close Monday 13 May.

ANZUP Mundipharma Clinical Research Fellowship

Mundipharma and ANZUP are partnering to support the Uro-Oncology Clinical Research Fellowship (CRF) valued at $60,000. The Mundipharma ANZUP CRF supports an early/mid-career clinician or researcher of any health care discipline. Applications close Friday 24 May with the Mundipharma Fellow announced at the 2019 ANZUP ASM.

For more information and application forms visit the ANZUP website under Grants & Awards > Awards & Fellowships (https://www.anzup.org.au/content.aspx?page=awardsandfellowships)
RUDE FOOD CAMPAIGN

Food for thought – Top chefs help ANZUP fight ‘below the belt’ cancers

In February, ANZUP’s ‘Rude Food’ campaign launched across social media channels Instagram and Facebook.

The ‘Rude Food’ campaign was designed to get the message out about how clinical trial research into ‘below the belt’ cancers is improving health outcomes for patients with prostate, testicular, kidney, penile and bladder cancer and the community.

With over 30 local and international top chefs including Manu Feildel, Ainsley Harriot and Fast Ed got behind the campaign and created ‘Rude Food’ dishes with subtle nods to the anatomy that ANZUP focuses our clinical research on, with a message on why they were involved.

The campaign continued to gain momentum, and in March won the Best Social Media Campaign at the BJUI Journal Social Media Awards held at the EAU19 meeting in Barcelona.

Over 65 media outlets across print, social and radio also covered the campaign.

The idea behind the campaign was to encourage discussion about these cancers and raise funds for the vital research needed to find preventions and treatments. ANZUP and the chefs encouraged everyone to get involved and create their own ‘Rude Food’ dish and share it with their friends, family & colleagues.

“The ‘Rude Food’ campaign aims to engage men and women in monitoring their health ‘below the belt’ while learning more about the importance of clinical trial research and how they can get involved,” says Margaret McJannett.

‘The campaign objectives were to encourage people to get checked for ‘below the belt’ cancers, generate awareness about the importance of clinical trials in improving treatment and outcomes and to encourage people to ask their doctor ‘Is there is a clinical trial suitable for me?’

Everyone has been touched by cancer in some way and it can be difficult to know where to start.

You can see more of the campaign on Instagram - https://www.instagram.com/anzuptrials/ and it’s not too late to get involved and to create your cheeky ‘Rude Food’ dish and share it to your social media networks tagging @anzuptrials with the hashtag #rudefood.
RUDE FOOD CAMPAIGN

#rudefood campaign highlights

- 2,342,721 TOTAL IMPRESSIONS
- VOTED BEST SOCIAL MEDIA CAMPAIGN AT THE BJUI JOURNAL SOCIAL MEDIA AWARDS
- 6,446 NEW PROFILE VISITS
- 450 FRIENDS OF ANZUP SIGNUPS
- 65 MEDIA OUTLETS COVERED THE CAMPAIGN
- 16,136 FACEBOOK IMPRESSIONS

#EAU19 @BJUiljournal #UroSoMe
Best Social Media Campaign goes to @ANZUPtrials @shottik, collected by @NiranjanJS
Anzup Update Autumn 2019 | 17

OTHER NEWS

Australia Day Honours
ANZUP congratulates 2019 Australia Day Honours List.

Professor Sanchia Aranda was awarded an AM recognising her significant service to community health, particularly to cancer control and nursing.

Professor Afaf Girgis was awarded an AM recognising her significant service to medicine and medical education in the field of cancer control and psycho-oncology.

Max Shub was awarded the OAM for service to community health, recognising his tireless advocacy for cancer patients and their families.

We are proud to work alongside you all.

Hello and goodbye

Farewell Prof. Helen Zorbas – outgoing Cancer Australia CEO
ANZUP Cancer Trials Group has gone from an idea to an international force in only ten years. ANZUP has had valuable support from Cancer Australia throughout. Helen has always been an amazing supporter, always accessible and responsive, having opened our meeting and spoken on several occasions, and always providing useful advice. We consider her a great Friend of ANZUP. We will certainly miss her cheerful and ready engagement and willingness to help however she can.

Welcome Jaclyn
In April we welcomed Jaclyn Verghis into the Clinical Trials Project Manager role. Jaclyn has worked in clinical trials coordination and data management for several years, beginning her career in the gastrointestinal service at Memorial Sloan Kettering Cancer Centre through to the NHMRC Clinical Trials Centre. She has worked alongside various cancer cooperative trials groups representing different disease areas and treatment in gastrointestinal, brain and lung cancers as well as in radiotherapy and surgical trials. Jaclyn’s experience ranges from study start up to close out, in pilot, phase II, III and registration studies, as well as in large cohort studies and biobank registries.

Welcome Nicole
Nicole Tankard has over 15 years’ communications experience, and has worked across a range of industries including financial services, professional services, telecommunications and energy. Nicole holds a Bachelor Degree in Communications majoring in Public Relations and Marketing and joined ANZUP in February 2019.

Welcome Claudia
Claudia Brooks joined ANZUP as Marketing & Communications Officer in April. Having spent three years studying in London, she returned to Australian shores in 2016 and worked in communications for not-for-profits Opportunity International and ReachOut Australia, before joining the ANZUP team.

Welcome Shalini
In February we welcomed Shalini Subramaniam as an ANZUP fellow. Having worked as a Medical Oncology Fellow at Campbelltown Hospital, she previously completed her training through St. Vincent’s Hospital. Working alongside Alison Zhang, Shalini’s fellowship is covering the ANZUP trials. Welcome Shalini!

Australia Day Honours
Professor Sanchia Aranda was awarded an AM recognising her significant service to community health, particularly to cancer control and nursing.

Professor Afaf Girgis was awarded an AM recognising her significant service to medicine and medical education in the field of cancer control and psycho-oncology.

Max Shub was awarded the OAM for service to community health, recognising his tireless advocacy for cancer patients and their families.

We are proud to work alongside you all.

Hello and goodbye
Farewell Prof. Helen Zorbas – outgoing Cancer Australia CEO
ANZUP Cancer Trials Group has gone from an idea to an international force in only ten years. ANZUP has had valuable support from Cancer Australia throughout. Helen has always been an amazing supporter, always accessible and responsive, having opened our meeting and spoken on several occasions, and always providing useful advice. We consider her a great Friend of ANZUP. We will certainly miss her cheerful and ready engagement and willingness to help however she can.

Welcome Jaclyn
In April we welcomed Jaclyn Verghis into the Clinical Trials Project Manager role. Jaclyn has worked in clinical trials coordination and data management for several years, beginning her career in the gastrointestinal service at Memorial Sloan Kettering Cancer Centre through to the NHMRC Clinical Trials Centre. She has worked alongside various cancer cooperative trials groups representing different disease areas and treatment in gastrointestinal, brain and lung cancers as well as in radiotherapy and surgical trials. Jaclyn’s experience ranges from study start up to close out, in pilot, phase II, III and registration studies, as well as in large cohort studies and biobank registries.

Welcome Nicole
Nicole Tankard has over 15 years’ communications experience, and has worked across a range of industries including financial services, professional services, telecommunications and energy. Nicole holds a Bachelor Degree in Communications majoring in Public Relations and Marketing and joined ANZUP in February 2019.

Welcome Claudia
Claudia Brooks joined ANZUP as Marketing & Communications Officer in April. Having spent three years studying in London, she returned to Australian shores in 2016 and worked in communications for not-for-profits Opportunity International and ReachOut Australia, before joining the ANZUP team.

Welcome Shalini
In February we welcomed Shalini Subramaniam as an ANZUP fellow. Having worked as a Medical Oncology Fellow at Campbelltown Hospital, she previously completed her training through St. Vincent’s Hospital. Working alongside Alison Zhang, Shalini’s fellowship is covering the ANZUP trials. Welcome Shalini!
Welcome Elizabeth
– our first WEHI/ANZUP Clinical Research Fellow
Please join us in welcoming Elizabeth Liow as the first Walter and Eliza Hall Institute (WEHI) and ANZUP Clinical Research Fellow (CRF). Elizabeth started in April this year in this new position, based at WEHI and supervised by Ben Tran.

Through a collaboration between WEHI and ANZUP, this part-time CRF position was created to support ANZUP clinical trials research. Elizabeth will bring her expertise to ANZUP where she will focus on supporting ANZUP’s clinical trial portfolio. Additionally, Elizabeth will assist in increasing ANZUP engagement and support across other ANZUP research activities. Welcome to the ANZUP team Elizabeth!

Welcome Al
Al Martin joined the ANZUP team as Executive Assistant to the CEO in April 2019, with over 17 years of experience in practice management and medical/hospital administration. Following eight years in medical oncology working for the amazing Prof Eva Segelov, Al brings a wealth of knowledge and passion to her role at ANZUP. Welcome Al!

Farewell Gillian
After more than two years at ANZUP we are sorry to say goodbye to our Marketing & Communications Officer Gillian Bailey. Gillian has been a great support to the ANZUP team over the past two years, and we wish her all the best in her next venture!

Farewell Christine
We are sad to say farewell to ANZUP’s Executive Assistant, Christine Garforth, after nearly 3 years with the team. Christine has been a dedicated and essential member of ANZUP during her time with us and we wish her every success in her new career in Pastoral Care/Chaplaincy. Good luck, Christine!

Ride and Support Your Research Fund
Tuesday 10 September 2019
Join us in the race to defeat prostate, bladder, kidney, penile and testicular cancers

Will you be lining up in 2019 for an action packed day at Sydney Motorsport Park?

The Below the Belt Pedalthon welcomes all levels of cyclists to ride as many laps as you can around the iconic Sydney track, with entertainment, awards, prizes and a post-race lunch. Help us raise much needed funds to help progress YOUR ideas to clinical trials and ultimately improve treatments and outcomes for those living with below the belt cancers.

All funds raised from the Pedalthon go directly to the Below the Belt Research Fund.

Together we can fight cancer below the belt

www.belowthebelt.org.au #BTBPedal19 #SYDPedal19
## UPCOMING EVENTS IN 2019

<table>
<thead>
<tr>
<th>Event Details</th>
<th>Dates</th>
<th>Location</th>
</tr>
</thead>
</table>
| **MAY**
| ANZUP PROSTATE CONCEPT DEVELOPMENT WORKSHOP | 17 May | Sydney |
| **MAY/JUNE**
| ASCO ANNUAL MEETING | 31-4 June | Chicago |
| | ANZCHOG ANNUAL SCIENTIFIC MEETING | 13 June | Christchurch, New Zealand |
| | CANCER NURSES SOCIETY OF AUSTRALIA 21ST ANNUAL CONGRESS | 20-22 June | Melbourne |
| | MASCC/ISOO SUPPORTIVE CARE IN CANCER | 21-23 June | San Francisco |
| **JULY**
| ANZUP ASM | 21-23 July | Hilton, Brisbane |
| | ANZBCTG ASM | 24-26 July | |
| **AUGUST**
| AUSTRALIAN PROSTATE CANCER CONFERENCE | 22-25 August | Melbourne |
| | APCCC 2019 | 29-31 August | St Gallen, Switzerland |
| | SYDNEY PEDALTHON | 10 September | |
| | ESMO | 27-1 October | Barcelona |
| **OCTOBER**
| NZ SECTION MEETING (USANZ) | 24-26 October | |
| | RANZCR ASM | 17-20 November | Auckland |
| | COSA ASM | 12-14 November | Adelaide |
| | ANZUP PRECEPTORSHIP (BLADDER, KIDNEY, TESTICULAR) | 29-30 November | Sydney |
Program highlights include:

- Leading international and Australian experts
- Up-to-date management and research for prostate and other genitourinary cancers
- PCFA ANZUP Nurses Symposium
- Translational Research Symposium
- Clinical trial Concept Development Workshop
- Overviews of current and planned ANZUP trials
- ANZUP MDT Masterclasses with expert panels
- Community Engagement Forum: A little below the belt
- Travel fellowships available for ANZUP members!

Our outstanding international faculty includes:

- **Alison Birtle** – Consultant Clinical Oncologist and Honorary Clinical Senior Lecturer, Lancashire Teaching Hospitals, UK
- **Catherine Paterson** – Associate Professor, Department of Nursing and Midwifery, Urology Researcher, University of Canberra
- **J. Kellogg (Kelly) Parsons** – Professor of Urology, UC San Diego Health, US
- **Elizabeth Plimack** – Chief, Division of Genitourinary Medical Oncology, Fox Chase Cancer Centre, US
- **Phuoc T. Tran** – Associate Professor of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins, US